Houte Hans Van Sells 2,490 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,490 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the transaction, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, May 2nd, Houte Hans Van sold 3,499 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17.

Nurix Therapeutics Stock Performance

Shares of NRIX stock traded down $0.48 during trading on Tuesday, hitting $20.77. 505,988 shares of the company were exchanged, compared to its average volume of 977,450. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -7.11 and a beta of 2.22. The business’s 50-day simple moving average is $18.96 and its 200 day simple moving average is $14.66. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $24.38.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. On average, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NRIX. Vanguard Group Inc. lifted its stake in Nurix Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock valued at $21,339,000 after acquiring an additional 22,804 shares during the last quarter. SG Americas Securities LLC lifted its stake in Nurix Therapeutics by 28.9% in the fourth quarter. SG Americas Securities LLC now owns 26,601 shares of the company’s stock valued at $275,000 after acquiring an additional 5,962 shares during the last quarter. Raymond James & Associates lifted its stake in Nurix Therapeutics by 3.1% in the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock valued at $1,042,000 after acquiring an additional 3,018 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $1,175,000.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NRIX shares. Stifel Nicolaus reiterated a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, May 15th. Robert W. Baird boosted their price target on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. Piper Sandler restated an “overweight” rating and set a $35.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, June 5th. Stephens began coverage on shares of Nurix Therapeutics in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada lifted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.82.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.